YR0155
Human PCSK9 Monoclonal Antibody, Endotoxin 0.05 EU/mg
Größe
£1,617.00
- SKU:
- YR0155
- Zusätzliche Namen:
- FH3, FHCL3, HCHOLA3, LDLCQ1, NARC-1, NARC1, PC9
- Anwendung:
- ELISA, FuncS, Neutralisation
- Molekulargewicht:
- 150 kDa
- Reinheit:
- >95%
- Lagerbedingungen:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Hersteller:
- Abclonal
- Immunogen:
- Human PCSK9
- Formulierung:
- Purified from cell culture supernatant in an animal-free facility
- Uniprot:
- Q8NBP7
- Synonyme:
- convertase subtilisin/kexin type 9 preproprotein;FH3;FHCL3;HCHOLA3;LDLCQ1;NARC-1;NARC1;neural apoptosis regulated convertase 1;Neural apoptosis-regulated convertase 1;PC9;Proprotein convertase 9;proprotein convertase subtilisin/kexin type 9;subtilisin/kexin-like protease PC9
- Weitere Details:
- What is evolocumab biosimilar research grade? Evolocumab (trade name Repatha) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. The PCSK9 protein targets LDL receptors for degradation. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR, in turn preventing PCSK9-mediated LDLR degradation and permitting the LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, evolocumab increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels. Evolocumab biosimilar uses the same protein sequences as the therapeutic antibody evolocumab.
- Versandbedingungen:
- Blue Ice